Springhill Fund Asset Management HK Co Ltd Makes New $3.09 Million Investment in Dyne Therapeutics, Inc. (NASDAQ:DYN)

Springhill Fund Asset Management HK Co Ltd purchased a new stake in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) during the 4th quarter, HoldingsChannel.com reports. The institutional investor purchased 131,200 shares of the company’s stock, valued at approximately $3,091,000. Dyne Therapeutics comprises approximately 5.0% of Springhill Fund Asset Management HK Co Ltd’s portfolio, making the stock its 11th largest holding.

A number of other hedge funds have also modified their holdings of the stock. Norges Bank acquired a new stake in Dyne Therapeutics in the fourth quarter valued at approximately $22,384,000. State Street Corp boosted its holdings in Dyne Therapeutics by 13.8% in the third quarter. State Street Corp now owns 3,641,859 shares of the company’s stock worth $130,816,000 after purchasing an additional 440,890 shares in the last quarter. Barclays PLC increased its position in Dyne Therapeutics by 162.2% during the third quarter. Barclays PLC now owns 207,309 shares of the company’s stock worth $7,446,000 after buying an additional 128,246 shares during the last quarter. Raymond James Financial Inc. bought a new position in Dyne Therapeutics during the fourth quarter valued at about $2,340,000. Finally, Geode Capital Management LLC boosted its stake in shares of Dyne Therapeutics by 4.8% during the 3rd quarter. Geode Capital Management LLC now owns 1,859,413 shares of the company’s stock worth $66,802,000 after acquiring an additional 84,760 shares in the last quarter. 96.68% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Dyne Therapeutics

In other Dyne Therapeutics news, insider Oxana Beskrovnaya sold 2,598 shares of the business’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $13.95, for a total value of $36,242.10. Following the transaction, the insider now owns 199,087 shares of the company’s stock, valued at approximately $2,777,263.65. The trade was a 1.29 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders have sold a total of 6,237 shares of company stock worth $77,760 over the last ninety days. Corporate insiders own 20.77% of the company’s stock.

Dyne Therapeutics Trading Down 12.1 %

Shares of DYN opened at $8.28 on Friday. The stock has a 50 day simple moving average of $12.81 and a 200-day simple moving average of $22.61. The stock has a market cap of $936.64 million, a PE ratio of -2.33 and a beta of 1.21. Dyne Therapeutics, Inc. has a 1 year low of $8.15 and a 1 year high of $47.45.

Dyne Therapeutics (NASDAQ:DYN) last issued its quarterly earnings data on Tuesday, March 4th. The company reported ($0.88) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.04. On average, sell-side analysts forecast that Dyne Therapeutics, Inc. will post -3.44 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on DYN. JPMorgan Chase & Co. decreased their target price on Dyne Therapeutics from $18.00 to $17.00 and set a “neutral” rating for the company in a research report on Friday, March 21st. Royal Bank of Canada reaffirmed an “outperform” rating and set a $45.00 price objective on shares of Dyne Therapeutics in a report on Tuesday, January 14th. Chardan Capital reissued a “buy” rating and set a $50.00 target price on shares of Dyne Therapeutics in a research report on Monday, March 17th. Guggenheim reaffirmed a “buy” rating on shares of Dyne Therapeutics in a research report on Friday, January 24th. Finally, BMO Capital Markets started coverage on Dyne Therapeutics in a report on Wednesday, March 12th. They set an “outperform” rating and a $50.00 price target for the company. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, twelve have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $47.46.

Dyne Therapeutics Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.